Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Cash (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Change in Cash for 7 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For Q3 2025, Change in Cash rose 191.03% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.7 million, up 127.2%, while the annual FY2024 figure was -$4.3 million, 25.33% up from the prior year.
  • Change in Cash hit $1.6 million in Q3 2025 for Cyclerion Therapeutics, up from -$633000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $25.1 million in Q2 2021 and bottomed at -$13.0 million in Q1 2021.
  • Average Change in Cash over 5 years is -$2.8 million, with a median of -$1.7 million recorded in 2024.
  • On a YoY basis, Change in Cash climbed as much as 336.24% in 2021 and fell as far as 185.5% in 2021.
  • Cyclerion Therapeutics' Change in Cash stood at -$8.5 million in 2021, then rose by 17.78% to -$7.0 million in 2022, then skyrocketed by 78.11% to -$1.5 million in 2023, then soared by 123.42% to $360000.0 in 2024, then soared by 333.89% to $1.6 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $1.6 million, -$633000.0, and $407000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.